Akebia Therapeutics
Akebia Therapeutics, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for patients with kidney disease. Founded in 2007, Akebia has made significant strides in the industry, particularly in the area of hypoxia-inducible factor (HIF) biology, which underpins its unique approach to treating renal conditions. The company’s flagship product, vadadustat, is designed to address anaemia associated with chronic kidney disease, setting it apart with its oral administration and mechanism of action. Akebia's commitment to advancing renal care has positioned it as a notable player in the biopharmaceutical landscape, with a strong emphasis on research and development. With a growing portfolio and strategic partnerships, Akebia Therapeutics continues to make impactful contributions to the field of nephrology.
DitchCarbon Score
How does Akebia Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Akebia Therapeutics's score of 3 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Akebia Therapeutics's reported carbon emissions
Akebia Therapeutics, headquartered in the US, currently does not have publicly available data on its carbon emissions, as there are no reported figures for emissions in kg CO2e. Additionally, the company has not outlined specific reduction targets or initiatives related to its carbon footprint. Without concrete emissions data or defined climate commitments, it is challenging to assess Akebia's environmental impact or its strategies for addressing climate change. As the industry increasingly prioritises sustainability, it will be important for Akebia to establish clear climate goals and transparency in its emissions reporting to align with best practices in environmental stewardship.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Akebia Therapeutics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
